$MCAA
Mountain & Co I Acquisition Corp

2024 Q1 Form 10-Q Financial Statement

#000110465924103221 Filed on September 27, 2024

View on sec.gov

Income Statement

Concept 2024 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $455.3K
YoY Change -12.52%
Operating Profit -$455.2K
YoY Change -12.52%
Interest Expense $1.329M
YoY Change -37.85%
% of Operating Profit
Other Income/Expense, Net $1.329M
YoY Change -37.85%
Pretax Income $873.6K
YoY Change -46.0%
Income Tax
% Of Pretax Income
Net Earnings $873.5K
YoY Change -46.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.05
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.20K
YoY Change -74.74%
Cash & Equivalents $19.20K
Short-Term Investments
Other Short-Term Assets $7.970K
YoY Change -97.39%
Inventory
Prepaid Expenses $7.973K
Receivables
Other Receivables
Total Short-Term Assets $27.17K
YoY Change -92.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $96.02M
YoY Change -25.78%
Total Long-Term Assets $96.02M
YoY Change -25.78%
TOTAL ASSETS
Total Short-Term Assets $27.17K
Total Long-Term Assets $96.02M
Total Assets $96.04M
YoY Change -25.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00
YoY Change
Accrued Expenses $2.186M
YoY Change 215.66%
Deferred Revenue
YoY Change
Short-Term Debt $5.047M
YoY Change 368.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.364M
YoY Change 332.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $8.050M
YoY Change 0.0%
Total Long-Term Liabilities $8.050M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.364M
Total Long-Term Liabilities $8.050M
Total Liabilities $16.41M
YoY Change 64.44%
SHAREHOLDERS EQUITY
Retained Earnings -$16.39M
YoY Change 70.67%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$16.39M
YoY Change
Total Liabilities & Shareholders Equity $96.04M
YoY Change -25.97%

Cashflow Statement

Concept 2024 Q1
OPERATING ACTIVITIES
Net Income $873.5K
YoY Change -46.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$118.3K
YoY Change 53.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $34.59M
YoY Change -69.17%
Cash From Investing Activities $34.59M
YoY Change -69.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -34.52M
YoY Change -69.2%
NET CHANGE
Cash From Operating Activities -118.3K
Cash From Investing Activities 34.59M
Cash From Financing Activities -34.52M
Net Change In Cash -49.34K
YoY Change -217.97%
FREE CASH FLOW
Cash From Operating Activities -$118.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://www.Mountainacquisitioncorp.com/20240331#SponsorMember
CY2023Q4 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://www.Mountainacquisitioncorp.com/20240331#SponsorMember
CY2024Q1 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://www.Mountainacquisitioncorp.com/20240331#SponsorMember
CY2023Q4 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://www.Mountainacquisitioncorp.com/20240331#SponsorMember
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001856995
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 mcaau Threshold Business Days For Redemption Of Public Shares
ThresholdBusinessDaysForRedemptionOfPublicShares
P10D
CY2024Q1 mcaau Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination
RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination
P2D
CY2024Q1 mcaau Stockholders Percentage Of Vote For Certain Actions
StockholdersPercentageOfVoteForCertainActions
0.006667
CY2024Q1 mcaau Stockholders Percentage Of Vote For Certain Actions
StockholdersPercentageOfVoteForCertainActions
0.006667
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
MOUNTAIN & CO. I ACQUISITION CORP.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41021
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4001 Kennett Pike, Suite 302
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19807
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19807
CY2024Q1 dei City Area Code
CityAreaCode
302
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
273 0765
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 us-gaap Cash
Cash
19197
CY2023Q4 us-gaap Cash
Cash
68536
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
600000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7973
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1307
CY2024Q1 us-gaap Assets Current
AssetsCurrent
27170
CY2023Q4 us-gaap Assets Current
AssetsCurrent
669843
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
96015382
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
129271658
CY2024Q1 us-gaap Assets
Assets
96042552
CY2023Q4 us-gaap Assets
Assets
129941501
CY2024Q1 mcaau Accrued Offering Costs
AccruedOfferingCosts
2185709
CY2023Q4 mcaau Accrued Offering Costs
AccruedOfferingCosts
1872078
CY2023Q4 mcaau Payable Into Trust Account Current
PayableIntoTrustAccountCurrent
600000
CY2024Q1 mcaau Due To Related Party
DueToRelatedParty
583841
CY2023Q4 mcaau Due To Related Party
DueToRelatedParty
553841
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
4327666
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3777666
CY2024Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
718945
CY2024Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
548305
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8364466
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6803585
CY2024Q1 mcaau Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
8050000
CY2023Q4 mcaau Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
8050000
CY2024Q1 us-gaap Liabilities
Liabilities
16414466
CY2023Q4 us-gaap Liabilities
Liabilities
14853585
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16387871
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14784317
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-16387296
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14783742
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96042552
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129941501
CY2024Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
455249
CY2023Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
520423
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-455249
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-520423
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1334503
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
2138060
CY2024Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-5709
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1328794
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2138060
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
873545
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1617637
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14783742
CY2024Q1 mcaau Adjustment To Equity Upon Initial Recognition Of Embedded Derivative Liability
AdjustmentToEquityUponInitialRecognitionOfEmbeddedDerivativeLiability
542596
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1934503
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
873545
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-16387296
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8240843
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2978061
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1617637
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9601267
CY2024Q1 us-gaap Profit Loss
ProfitLoss
873545
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1617637
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1334503
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2138060
CY2024Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-5709
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6666
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-43062
CY2024Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-313631
CY2023Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-112873
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
600000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
257478
CY2024Q1 mcaau Increase Decrease In Payable Into Trust Account
IncreaseDecreaseInPayableIntoTrustAccount
600000
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
30000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
30000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-118284
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77010
CY2024Q1 mcaau Payment For Extension Contributions In Trust Account
PaymentForExtensionContributionsInTrustAccount
1200000
CY2023Q1 mcaau Payment For Extension Contributions In Trust Account
PaymentForExtensionContributionsInTrustAccount
840000
CY2024Q1 mcaau Proceeds From Withdrawal From Trust Account In Connection With Redemption
ProceedsFromWithdrawalFromTrustAccountInConnectionWithRedemption
35790779
CY2023Q1 mcaau Proceeds From Withdrawal From Trust Account In Connection With Redemption
ProceedsFromWithdrawalFromTrustAccountInConnectionWithRedemption
113049318
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34590779
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
112209318
CY2024Q1 mcaau Payments For Redemptions
PaymentsForRedemptions
35790779
CY2023Q1 mcaau Payments For Redemptions
PaymentsForRedemptions
113049318
CY2024Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
550000
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
958833
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
718945
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-34521834
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-112090485
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49339
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41823
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68536
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34186
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19197
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76009
CY2024Q1 mcaau Accretion Of Class Common Stock Subject Redemption To Redemption Value
AccretionOfClassCommonStockSubjectRedemptionToRedemptionValue
2094503
CY2023Q1 mcaau Accretion Of Class Common Stock Subject Redemption To Redemption Value
AccretionOfClassCommonStockSubjectRedemptionToRedemptionValue
2978061
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND LIQUIDITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mountain &amp; Co. I Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on April 16, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses or entities (the “Business Combination”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Company had not commenced any operations. All activity through March 31, 2024 relates to the Company’s formation and the initial public offering (“IPO”) described below. The Company will not generate any operating revenues at the earliest until after the completion of its initial Business Combination. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s sponsor is Mountain &amp; Co. I Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s IPO was declared effective on November 4, 2021 (the “Effective Date”). On November 9, 2021, the Company consummated its IPO of 20,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit, which is discussed in Note 3 (the “Public Offering”) and the sale of 12,000,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering. On November 12, 2021, the underwriters exercised their full over-allotment option, resulting in an addition 3,000,000 units purchased and $30,000,000 in additional gross proceeds for aggregate units purchased of 23,000,000 and aggregate gross proceeds of $230,000,000 from both the IPO and over-allotment option exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transaction costs related to the IPO and the exercise of the over-allotment option amounted to $13,406,427 consisting of $4,600,000 of underwriting commissions, $8,050,000 of deferred underwriting fees and $756,427 of other cash offering costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company must consummate an initial Business Combination with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the trust account (as defined below) (excluding the amount of any deferred underwriting discount held in trust) at the time of its signing a definitive agreement in connection with the initial Business Combination. However, the Company will only complete such Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company does not believe that its anticipated principal activities will subject them to the Investment Company Act. To this end, the proceeds held in the trust account may only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), the Company intends to avoid being deemed an “investment company” within the meaning of the Investment Company Act. The IPO offering is not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of its obligation to provide holders of the Company’s Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of public shares if the Company does not complete its initial Business Combination by November 9, 2024 or (B) with respect to any other provision relating to the rights of holders of Class A ordinary shares; or (iii) absent its completing an initial Business Combination within 15 months from the closing of this offering (or up to 18 months from the closing of this offering if we extend the period of time to consummate a Business Combination), the return of the funds held in the trust account to the public shareholders as part of the redemption of the public shares. If the Company does not invest the proceeds as discussed above, the Company may be deemed to be subject to the Investment Company Act. Although the Company expects to enter into an agreement with a target company for a business combination no later than 18 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">months after, and to consummate a business combination prior to the 24 month anniversary of, its IPO, should the Company be unable to do so, the Company intends to instruct Continental Stock Transfer &amp; Trust Company, the trustee with respect to the trust account, to liquidate the U.S. government securities or money market funds held in the trust account and thereafter to hold all funds in the trust account in cash until the earlier of consummation of the Company’s business combination or liquidation, to mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act. If the Company were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which the Company has not allotted funds and may hinder the ability to complete a Business Combination. If the Company has not consummated the initial Business Combination within the required time period, the public shareholders may receive only approximately $10.30 per public share, or less in certain circumstances, on the liquidation of the trust account and the warrants will expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the IPO on November 9, 2021, and subsequent close of the over-allotment option exercise on November 12, 2021, a total of $236,900,000, comprised of $225,400,000 of the net proceeds from the IPO, including $8,050,000 of the underwriters’ deferred discount, and $11,500,000 of the proceeds of the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer &amp; Trust Company, acting as trustee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of the initial Business Combination either (i) in connection with a general meeting called to approve the initial Business Combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement or whether the Company were deemed to be a foreign private issuer (which would require a tender offer rather than seeking shareholder approval under SEC rules). The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of <span style="-sec-ix-hidden:Hidden_bvLP6nnwikCA3U_ZvLu-Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.30 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ordinary shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company has not consummated an initial Business Combination by November 9, 2024, the proceeds then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to pay income taxes, if any (less up to $100,000 of interest to pay dissolution expenses), will be used to fund the redemption of its public shares, as further described herein. Any redemption of public shareholders from the trust account will be effected automatically by function of the amended and restated memorandum and articles of association prior to any voluntary winding up. If the Company were required to wind up, liquidate the trust account and distribute such amount therein, pro rata, to its public shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions of the Companies Act. In that case, investors may be forced to wait beyond November 9, 2024 before the redemption proceeds of the trust account become available to them, and they receive the return of their pro rata portion of the proceeds from the trust account. The Company has no obligation to return funds to investors prior to the date of the redemption or liquidation unless, prior thereto, the Company consummated its initial Business Combination or amend certain provisions of the amended and restated memorandum and articles of association, and only then in cases where investors have sought to redeem their Class A ordinary shares. Only upon the redemption or any liquidation will public redemptions be entitled to distributions if the Company does not complete its initial Business Combination and do not amend certain provisions of the amended and restated memorandum and articles of association. The amended and restated memorandum and articles of association will provide that, if the Company winds up for any other reason prior to the consummation of its initial Business Combination, the Company will follow the foregoing procedures with respect to the liquidation of the trust account as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_Up-eN-0n-kqBMFavmEMQMw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, subject to applicable Cayman Islands law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their Founder Shares and public shares in connection with the completion of the initial Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the public shares if the Company has not consummated an initial Business Combination within the Combination Period or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial Business Combination activity; (iii) waive their rights to liquidating distributions from the trust account with respect to their Founder Shares if the Company fails to complete its initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame; and (iv) vote any Founder Shares held by them and any public shares purchased during or after the Public Offering (including in open market and privately-negotiated transactions) in favor of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2023, the Company held an extraordinary general meeting of shareholders, where our shareholders approved a special resolution (the “Extension Amendment Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from February 9, 2023 to November 9, 2023 (the “Extension”), the date by which the Company must consummate an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote to approve the Extension Amendment Proposal, shareholders holding 10,784,962 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the trust account. As a result, approximately $113.0 million (approximately $10.48 per share) was removed from the trust account to pay such redeeming holders. After that 12,215,038 of the public shares issued in our IPO remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Extension, the Sponsor agreed to advance to the Company (i) $420,000 plus (ii) $420,000 for each subsequent calendar month commencing on March 9, 2023, and on the 9th day of each subsequent month, or portion thereof, that the Company requires to complete a Business Combination, to be deposited in the trust account on or before the 9th day of each calendar month, until November 9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2023, the Company issued a promissory note (the “Note”) in the principal amount of up to $3,780,000 to the Sponsor, in connection with the Extension. The Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company’s initial business combination, or (b) the date of the liquidation of the Company. At the option of the Sponsor, up to $1,500,000 of the loan would be convertible into warrants identical to the Company’s private placement warrants, at $1.00 per warrant. Any amendments to the Note and the loan may be made with the written consent of the Sponsor and the Company. For example, if we determine that we no longer expect to complete a business combination within the prescribed time frame, the Sponsor and the Company may agree to discontinue such loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, the Sponsor has deposited seven monthly payments of $420,000 or $2,940,000 in total in connection with the Extension and under the Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2023, the Company held an extraordinary general meeting of shareholders, where our shareholders approved a special resolution (the “Second Extension Amendment Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from November 9, 2023 to March 9, 2024 (the “Second Extended Date”), the date by which the Company must consummate an initial business combination (the “Second Extension”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote to approve the Second Extension Amendment Proposal, shareholders holding 701,973 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the trust account. As a result, approximately $7.8 million (approximately $11.05 per share), was removed from the trust account to pay such redeeming holders. After that 11,513,065 of the public shares issued in our IPO remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Second Extension, the Sponsor agreed to, in its discretion, advance to the Company (i) $300,000 plus (ii) $300,000 for each subsequent calendar month commencing on October 9, 2023, and on the 9th day of each subsequent month, or portion thereof, that the Company requires to complete a Business Combination, to be deposited in the trust account on or before the 9th day of each calendar month, until the Second Extended Date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2023, the Company amended and restated that certain promissory note, dated February 6, 2023 (the “Amended and Restated Note”) previously issued by the Company to the Sponsor in respect of such advances and the Sponsor has waived any and all rights to the monies held in the trust account with respect to those advances. The Amended and Restated Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Company’s initial business combination, or (b) the date of the liquidation of the Company. At the option of the Sponsor, up to $1,500,000 of the loan would be convertible into warrants identical to the Company’s private placement warrants, at $1.00 per warrant. Any amendments to the Amended and Restated Note and the loan may be made with the written consent of the Sponsor and the Company. For example, if we determine that we no longer expect to complete a business combination within the prescribed time frame, the Sponsor and the Company may agree to discontinue such loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024, a payment of $1,200,000 had been made to the Trust Account in connection with the Second Extension and under the Note. As of December 31, 2023, the Sponsor had not made additional payments in connection with the Second Extension due on November 9, 2023 and December 9, 2023, respectively. The Sponsor had sole discretion whether to make such payments. However, payments of $300,000 for each calendar month commencing September 2023 and ending February 2024, or $1.8 million in the aggregate, were deposited into the Trust Account. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 8, 2024, we held an extraordinary general meeting of shareholders, where our shareholders approved a special resolution (the “Third Extension Amendment Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from March 9, 2024 to November 9, 2024 (the “Third Extension”), the date by which the Company must consummate an initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote to approve the Third Extension Amendment Proposal, shareholders holding 3,133,293 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the trust account. As a result, approximately $35.8 million (approximately $11.42 per share) was removed from the trust account to pay such redeeming holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subsequent to and in connection with the Second Extension, payments of $300,000 for each calendar month commencing September 2023 and ending February 2024, or $1.8 million in the aggregate, were deposited into the Trust Account. The aggregate deposit included $1.2 million for the four calendar months ended February 2024, loaned to the Company by several accredited investors in a private financing transaction that closed during the period from February 20, 2024 to February 23, 2024 (the “Financing”). In connection with the Financing, the Company issued to each investor a convertible promissory note (each such note, a “Financing Convertible Note”) evidencing the outstanding balance under such investor’s loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Third Extension, third-party investors were expected to advance to the Company (i) $160,000, to be deposited in the Company’s trust account (the “Trust Account”) on or about March 9, 2024, and (ii) $160,000 for each subsequent calendar month, or portion thereof, that the Company requires to complete a business combination until the end of the Third Extension, to be deposited in the Trust Account on or before the 9th day of each calendar month. As of the date of this quarterly report on Form 10-Q, none of these monthly payments of $160,000 have been deposited in the Trust Account. There can be no assurance that advances for subsequent such calendar months will be made. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.30 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.30 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for the initial Business Combination and redemptions could be reduced to less than $10.30 per public share. In such event, the Company may not be able to complete the initial Business Combination, and you would receive such lesser amount per share in connection with any redemption of your public shares. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity, Capital Resources and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2024, the Company had $19,197 in operating cash and a working capital deficit of $8,337,296.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs up to March 31, 2024 have been satisfied through the payment of certain offering costs by Sponsor of $25,000 (see Note 5) for the Founder Shares and the loan under an unsecured promissory note from the Sponsor of $500,000 (see Note 5). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as defined below (see Note 5). As of March 31, 2024 and December 31, 2023, there were no amounts outstanding under any Working Capital Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the period from February 20, 2024 to March 19, 2024, the Company issued to the third-party investors five convertible promissory notes (each, a “Convertible Note”) evidencing working capital loans made by such investors to the Company in an aggregate of $718,945.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Account Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined that the Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. In addition, the Company has until November 9, 2024 to consummate a Business Combination. Management considers that liquidity and capital resources available might not be sufficient to operate through November 9, 2024. Also, it is uncertain that the Company will be able to consummate a Business Combination by this date. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management has determined that the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, in addition to potential liquidity and capital shortage raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. On May 5, 2023, the World Health Organization declared that COVID-19 no longer constitutes a public health emergency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2024Q1 mcaau Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2021Q4 mcaau Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
23000000
CY2021Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230000000
CY2021Q4 mcaau Transaction Costs
TransactionCosts
13406427
CY2021Q4 mcaau Sale Of Stock Underwriting Fees
SaleOfStockUnderwritingFees
4600000
CY2021Q4 mcaau Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
8050000
CY2021Q4 mcaau Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
756427
CY2024Q1 mcaau Threshold Minimum Aggregate Fair Market Value As Percentage Of Assets Held In Trust Account
ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount
0.80
CY2024Q1 mcaau Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50
CY2024Q1 mcaau Maturity Period Of Investments In Money Market Funds
MaturityPeriodOfInvestmentsInMoneyMarketFunds
P185D
CY2024Q1 mcaau Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2024Q1 mcaau Number Of Months Within Consummated Initial Business Combination From Closing Of Offering To Redeem Shares
NumberOfMonthsWithinConsummatedInitialBusinessCombinationFromClosingOfOfferingToRedeemShares
P15M
CY2024Q1 mcaau Number Of Months If Entity Does Not Consummated Initial Business Combination Within15 Months From Closing Of Offering To Redeem Shares
NumberOfMonthsIfEntityDoesNotConsummatedInitialBusinessCombinationWithin15MonthsFromClosingOfOfferingToRedeemShares
P18M
CY2024Q1 mcaau Threshold Period To Enter Into Agreement For Business Combination
ThresholdPeriodToEnterIntoAgreementForBusinessCombination
P18M
CY2024Q1 mcaau Threshold Period To Consummate Business Combination
ThresholdPeriodToConsummateBusinessCombination
P24M
CY2024Q1 mcaau Redemption Price Per Share
RedemptionPricePerShare
10.30
CY2021Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
236900000
CY2021Q4 mcaau Underwriters Deferred Discount
UnderwritersDeferredDiscount
8050000
CY2024Q1 mcaau Redemption Price Per Share
RedemptionPricePerShare
10.30
CY2024Q1 mcaau Condition For Future Business Combination Threshold Net Tangible Assets
ConditionForFutureBusinessCombinationThresholdNetTangibleAssets
5000001
CY2024Q1 mcaau Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2024Q1 mcaau Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023Q1 mcaau Shareholders Exercised Right To Redeem For Number Of Shares
ShareholdersExercisedRightToRedeemForNumberOfShares
10784962
CY2023Q1 mcaau Amount Removed From Trust Account For Redemption Of Shares
AmountRemovedFromTrustAccountForRedemptionOfShares
113000000.0
CY2023Q1 mcaau Fund Held In Trust Account Per Public Share
FundHeldInTrustAccountPerPublicShare
10.48
CY2024Q1 mcaau Number Of Monthly Payments Deposited In Trust Account
NumberOfMonthlyPaymentsDepositedInTrustAccount
7
CY2023Q3 mcaau Shareholders Exercised Right To Redeem For Number Of Shares
ShareholdersExercisedRightToRedeemForNumberOfShares
701973
CY2023Q3 mcaau Amount Removed From Trust Account For Redemption Of Shares
AmountRemovedFromTrustAccountForRedemptionOfShares
7800000
CY2023Q3 mcaau Fund Held In Trust Account Per Public Share
FundHeldInTrustAccountPerPublicShare
11.05
CY2023Q3 mcaau Threshold Period To Deposit Amount In Trust Account For Each Calendar Month
ThresholdPeriodToDepositAmountInTrustAccountForEachCalendarMonth
P9D
CY2024Q1 mcaau Total Monthly Payments Deposited
TotalMonthlyPaymentsDeposited
1800000
CY2024Q1 mcaau Shareholders Exercised Right To Redeem For Number Of Shares
ShareholdersExercisedRightToRedeemForNumberOfShares
3133293
CY2024Q1 mcaau Amount Removed From Trust Account For Redemption Of Shares
AmountRemovedFromTrustAccountForRedemptionOfShares
35800000
CY2024Q1 mcaau Fund Held In Trust Account Per Public Share
FundHeldInTrustAccountPerPublicShare
11.42
CY2024Q1 mcaau Payments Deposited Per Month
PaymentsDepositedPerMonth
300000
CY2024Q1 mcaau Total Monthly Payments Deposited
TotalMonthlyPaymentsDeposited
1800000
CY2024Q1 mcaau Aggregate Payments Deposited For Four Calendar Months
AggregatePaymentsDepositedForFourCalendarMonths
1200000
CY2024Q1 mcaau Investment Of Proceeds In Trust Account
InvestmentOfProceedsInTrustAccount
160000
CY2024Q1 mcaau Amount Required To Be Deposited In Trust Account For Each Subsequent Calendar Month Or Portion Thereof
AmountRequiredToBeDepositedInTrustAccountForEachSubsequentCalendarMonthOrPortionThereof
160000
CY2024Q1 mcaau Threshold Period To Deposit Amount In Trust Account For Each Calendar Month
ThresholdPeriodToDepositAmountInTrustAccountForEachCalendarMonth
P9D
CY2024Q1 mcaau Amount Required To Be Deposited In Trust Account For Each Subsequent Calendar Month Or Portion Thereof
AmountRequiredToBeDepositedInTrustAccountForEachSubsequentCalendarMonthOrPortionThereof
160000
CY2024Q1 mcaau Redemption Price Per Share
RedemptionPricePerShare
10.30
CY2024Q1 mcaau Redemption Price Per Share
RedemptionPricePerShare
10.30
CY2024Q1 mcaau Redemption Price Per Share
RedemptionPricePerShare
10.30
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19197
CY2024Q1 mcaau Working Capital Deficit
WorkingCapitalDeficit
8337296
CY2024Q1 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
0
CY2023 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
0
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q3 mcaau Percentage Of Interest Rate In Trust Account
PercentageOfInterestRateInTrustAccount
0.0460
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
96015382
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
129271658
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
13406427
CY2024Q1 mcaau Temporary Equity Proceeds From Initial Public Offering
TemporaryEquityProceedsFromInitialPublicOffering
230000000
CY2023Q4 mcaau Temporary Equity Proceeds From Initial Public Offering
TemporaryEquityProceedsFromInitialPublicOffering
230000000
CY2024Q1 mcaau Temporary Equity Proceeds Allocated To Public Warrants
TemporaryEquityProceedsAllocatedToPublicWarrants
6900000
CY2023Q4 mcaau Temporary Equity Proceeds Allocated To Public Warrants
TemporaryEquityProceedsAllocatedToPublicWarrants
6900000
CY2024Q1 mcaau Temporary Equity Issuance Costs
TemporaryEquityIssuanceCosts
12963555
CY2023Q4 mcaau Temporary Equity Issuance Costs
TemporaryEquityIssuanceCosts
12963555
CY2024Q1 mcaau Temporary Equity Redemptions
TemporaryEquityRedemptions
156600865
CY2023Q4 mcaau Temporary Equity Redemptions
TemporaryEquityRedemptions
120810086
CY2024Q1 mcaau Fair Value Of Over Allotment Liability
FairValueOfOverAllotmentLiability
60000
CY2023Q4 mcaau Fair Value Of Over Allotment Liability
FairValueOfOverAllotmentLiability
60000
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 mcaau Units Issued During Period Shares New Issues
UnitsIssuedDuringPeriodSharesNewIssues
23000000
CY2024Q1 mcaau Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2023Q3 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
2537500
CY2023Q4 mcaau Minimum Cash Condition Intended To Cover Expenses
MinimumCashConditionIntendedToCoverExpenses
90000000
CY2023Q3 mcaau Capital Market Advisor Fee
CapitalMarketAdvisorFee
4000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 mcaau Board Of Directors Number Of Classes
BoardOfDirectorsNumberOfClasses
3
CY2024Q1 mcaau Board Of Directors Term
BoardOfDirectorsTerm
P3Y
CY2024Q1 mcaau Board Of Directors Number Of Classes Appointed Each Year
BoardOfDirectorsNumberOfClassesAppointedEachYear
1
CY2024Q1 mcaau Class B Shares Minimum Conversion Ratio To Class
ClassBSharesMinimumConversionRatioToClass
1
CY2024Q1 mcaau Common Stock Convertible Conversion Ratio
CommonStockConvertibleConversionRatio
1
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001104659-24-103221-index-headers.html Edgar Link pending
0001104659-24-103221-index.html Edgar Link pending
0001104659-24-103221.txt Edgar Link pending
0001104659-24-103221-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcaau-20240331.xsd Edgar Link pending
mcaau-20240331x10q.htm Edgar Link pending
mcaau-20240331xex31d1.htm Edgar Link pending
mcaau-20240331xex31d2.htm Edgar Link pending
mcaau-20240331xex32d1.htm Edgar Link pending
mcaau-20240331xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mcaau-20240331_cal.xml Edgar Link unprocessable
mcaau-20240331_def.xml Edgar Link unprocessable
mcaau-20240331_lab.xml Edgar Link unprocessable
mcaau-20240331_pre.xml Edgar Link unprocessable
mcaau-20240331x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending